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Advances in cellular and molecular immunology over the past
decade have revolutionized the way we think about interactions
between the immune system and parenchymal tissues. The
availability of well characterized experimental models of organ-
specific or systemic autoimmunity has allowed advances in
basic immunology to be incorporated into understanding the
basis for deviant immune responses resulting in host injury, as
well as the mechanisms of tolerance to organ-specific antigens
[1—5]. This review outlines a framework analysis for under-
standing how the immune system interacts with the interstitial
compartment of the kidney. This framework is comprised of
four sections. The first details requirements for the induction of
immune responses, including antigen expression in the kidney
and how such antigen is presented to the immune system. The
second section summarizes work from both experimental mod-
els and human studies which have characterized cell-mediated
immune responses in interstitial disease [6]. The third section is
an update of the antibody response to interstitial antigens, as
well as the role of antibody in the effector limb of the immune
response, an area which has been previously reviewed exten-
sively [3, 4]. The final section discusses how immune responses
to interstjtial antigens are typically regulated, either by the host
or through external manipulations, such that tolerance to organ-
specific antigens is maintained [7—9].
Antigen expression and presentation
In order for an immune response targeted to interstitial
antigens to be initiated, the antigen must be expressed within
the interstitial compartment of the kidney and must be immu-
nologically "visible" to the immune system. Polymorphisms in
target antigen expression define one level of susceptibility to
autoimmune nephritis. The target antigen of anti-tubular base-
ment membrane (aTBM) disease, for example, is not expressed
in all inbred rodent strains or all humans [10—12]. Circulating
immune products specific for this target antigen do not lead to
interstitial injury in such a host. Such polymorphisms in target
antigen expression underlie the occasional observation of
aTBM antibodies in renal allografts which react with graft, but
not native, kidney [121. The extent to which interstitial glyco-
proteins display polymorphism, aside from this one instance, is
largely unexplored.
Antigen visibility consists of several components in addition
to antigen presence in the interstitium. An antigen may not be
routinely exposed to circulating lymphocytes because of re-
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stricted localization, or it may not be visible because it has not
been processed in such a way to be recognizable to T cells. T
cells recognize peptide fragments of antigen in association with
either class II (CD4 cells) or class I (CD8 cells) major
histocompatibility complex (MHC) antigens [13—151. Cells
which present antigen to class 11-restricted CD4 T cells are
thought to endocytose the antigen, digest it within lysosomes,
and re-express peptide fragments of the antigen associated with
class II MHC [16, 171. This antigen-MHC association probably
occurs in a peptide "groove" in the class II antigen [181, as has
been demonstrated to exist on class I by crystallographic
structure [19, 20]. The effector limb of the cell-mediated nephri-
togenic immune response undoubtedly recognizes interstitial
glycoprotein antigens as peptides complexed with MHC anti-
gens of native renal cells, that is, tubular cells, interstitial
fibroblasts, or, perhaps, the endothelial cells of the interstitial
vascular network. How the afferent or inductive limb of the
cellular nephritogenic immune response is induced in vivo is
less clear. There are three major possibilities. The target
antigen may be presented to CD4 T helper (Th) cells by native
renal cells (tubular cells, fibroblasts, or tissue-based macro-
phages) in association with class II MHC [21, 221. Activated Th
cells then provide permissive help for both humoral and cell-
mediated effector immunity. Alternatively, the target antigen
may be endocytosed and processed by circulating antigen-
presenting cells (APCs), with T cell education occurring in the
peripheral lymphoid organs instead of locally within the kidney.
The third possibility is that the antigen inducing the immune
response is cross reactive with a kidney antigen. An infectious
agent or drug may be processed by APCs in peripheral lym-
phoid organs and activate antigen-specific Th cells. The effector
limb of this immune response would recognize both the stimu-
lating antigen as well as a cross reactive epitope expressed in
the interstitium. While this hypothesis of cross reactive anti-
gens as the basis for autoimmunity ("molecular mimicry" [231)
has much intrinsic appeal, there is not yet supportive evidence
for its relevance to kidney disease.
There is experimental evidence to support the hypothesis that
native renal cells can process and present antigen to T cells [21,
22, 24]. Murine proximal tubular epithelial cells (MCT) synthe-
size the 3M-l antigen and can present this antigen to CD4,
3M-l-specific T cells [21, 25]. This interaction obeys the "rules"
of classic APC-T cell interactions in that it can be blocked by
aCD4 or anti-class II antibodies [26, 27]. There are several
novel aspects to this interaction. APC's for class Il-restricted T
cells are not typically envisioned as presenting self antigens;
rather they endocytose, digest, and present exogenous antigens
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[16, 17]. Self antigens are thought to be predominantly ex-
pressed in the context of class I MHC molecules and recognized
by CD8 T cells. This distinction has arisen in part because
purified organ parenchymal cells and defined organ-specific
antigens are not widely available to test this hypothesis. Yet
there is precedent for such a phenomenon in other systems:
thyroid epithelial cells can support the proliferation of thyro-
globulin specific T cells [28].
The other novel aspect to the MCT interaction with 3M-i-
specific T cells is that it can be inhibited by antibodies to the
3M-l antigen [21]. Anti-antigen antibodies do not typically
interfere with antigen presentation. The structural explanation
for this is that the antibody cannot easily interact with a peptide
buried deep within a peptide "groove" in the MHC molecule
[20]. There are two major possible explanations as to why
a3M-1 antibodies inhibit stimulation of CD4 T cells by MCT
cells. The first is that the immunogenic peptide is not deeply
buried and is, therefore, accessible to the antibody. The other
possibility is that the antibody has an indirect effect on antigen
presentation. Recent evidence supports the latter hypothesis.
Anti-3M-i antibodies decrease class II MHC antigen expression
by MCT cells in vitro and by proximal tubular epithelium in
vivo [291. Nuclear run-off assays of nascent RNA transcripts
from MCT cells coincubated with a3M- 1 antibodies suggest that
this regulatory event occurs at a transcriptional level [29].
Instead of causing target cell damage, such an interaction
between autoantibodies and target cell may actually ameliorate
the intensity of cellular immune injury. This is clearly the case
in murine aTBM disease: class Il-restricted inflammatory ef-
fector T cells will mediate interstitial injury when class II
expression is heightened by gamma interferon (y-IFN) [29]. If
augmented class II expression is blocked with a3M-l antibod-
ies, class Il-restricted T cells are not nephritogenic. Class II
MHC expression by organ parenchymal cells is typically quite
low, and in part, this may be part of a collective peripheral
mechanism for maintaining tolerance. In the presence of inflam-
matory cells which produce y-IFN, however, class II levels rise
and tolerance may be bypassed. Antigen presentation by native
renal cells, therefore, may play a more important role in
maintaining chronic inflammation than in the initiation of tar-
geted autoimmune events.
Cellular immune responses to interstitial antigens
Early studies demonstrated that the interstitial compartment
of the kidney is vulnerable to cell-mediated hypersensitivity
reactions in a host appropriately sensitized to antigen [30, 31].
The adoptive transfer of an inflammatory lesion with immune T
cells, but not serum, is highly supportive evidence for an
important role for sensitized T cells [32]. Once a role has been
established, it is possible in some species to further study
discrete phenotypic and functional subsets of relevant T cells at
a cellular and molecular level, to better define and understand
the fine specificity and function of the cells. Th cells act as
inducer cells for both T and B cell-mediated effector mecha-
nisms. There are also T cells with effector function (Te; that is,
cytotoxicity, delayed type hypersensitivity) which are impor-
tant in eliciting interstitial injury. Lastly, T cells also play an
important role in bidirectionally modulating the activity of
helper and effector T cells. This section will discuss Th and Te
in the context of interstitial injury. The final section will discuss
T cell regulation.
T cell-mediated immunity in aTBM disease
Although the fully developed lesion of sTBM-associated
interstitial nephritis could not be transferred with immune cells
alone in rats and guinea pigs, early studies demonstrated that
sensitized T cells were an important component of the autoim-
mune lesion [33—36]. The role of T cells in mediating inflamma-
tory interstitial nephritis has been most extensively character-
ized in the murine model of aTBM disease. Two observations
provided the impetus for an in-depth analysis of the T cell
repertoire in this model. The first was that there were no
differences in humoral immunity between immunized suscepti-
ble and nonsusceptible strains of mice which could explain the
vastly different outcomes following immunization [37]. The
second observation was that transfer of immune T cells into
genetically compatible naive recipients predictably results in
mononuclear cell infiltration of the interstitium, progressive
fibrosis, and eventual organ failure [38]. The T cells required for
transfer of disease are present in the spleen and draining lymph
nodes of syngeneic, immunized SJL mice [39]. A combination
of in vivo and in vitro studies of relevant 3M-i specific T cells
has resulted in an integrated understanding of the events
required for differentiation and function of nephritogenic T
cells. Since the disease is induced by immunization, the matu-
ration of the T cell response can be studied from the time
antigen, in an immunogenic form, is introduced into the system.
Analysis of 3M-i reactive T cells in murine aTBM disease
Within several days of immunization with 3M-I, CD4 helper
T cells are proliferating in peripheral lymph nodes [39—41].
These Th cells recognize the 3M-i antigen in association with
class II antigens using conventional a:f3 heterodimers as T cell
antigen receptors (TcR) [41, 42]. It is interesting that MHC-
restricted, 3M-i-specific CD4 Th cells also undergo prolifera-
tive expansion following immunization of mice which are not
susceptible to disease [39, 43]. Resistance to disease, therefore,
can not be attributed to an inability to initiate a cell-mediated
immune response to 3M-i. Instead the fine specificity of this
cell-mediated response and its regulation are distinct between
susceptible and nonsusceptible mice [43, 44]. This is discussed
in more detail in the final section. There is an intriguing
distinction of potential significance between 3M-l specific Th
cells from susceptible and non-susceptible mice [39]. Th cells
from susceptible mice bear a cell-surface determinant which
reacts with a polyclonal antisera generated against idiotypes
expressed on aTBM antibodies eluted from nephritic kidneys.
3M-I reactive Th cells from non susceptible mice do not bear
this idiotype. Although the structural and molecular definition
of this idiotype on Th cells is under investigation, it likely is
related to TcR variable region gene products. The implication of
this finding is that the TcR variable region gene usage of
susceptible and nonsusceptible mice may differ.
The Th cells from susceptible mice do not directly mediate
interstitial nephritis, but they are required for the differentiation
of effector T cells which directly initiate interstitial inflamma-
tion [41—43]. Effector cells are defined as such by their ability to
acutely transfer interstitial nephritis: whereas 3M-i specific Th
cells lead to interstitial nephritis 6 to iO weeks following
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adoptive transfer, fully differentiated 3M-i specific T cells
result in interstitial inflammation after 5 to 7 days [41—43]. Such
effector T cells are CD3, CD8, CD4 and also bear an
idiotype cross reactive with that present on sTBM antibodies
eluted from nephritic kidneys. The CD8 effector cells recog-
nize peptide fragments of the 3M-I antigen in association with
class I MHC molecules (H2Ksd) [39, 40, 45]. This effector cell
mediates a delayed-type hypersensitivity response following
adoptive transfer into syngeneic recipients. This functional
property has facilitated analysis of the requirements for induc-
tion of these effector cells in vitro. The TUTH can be induced in
vitro in the presence of naive syngeneic splenocytes, antigen,
IL-2, and the aforementioned antigen-specific Th or superna-
tants from Th cells [41, 42]. Effector cells induced in vitro have
the same phenotype and fine specificity of those induced in
vivo, and are fully nephritogenic following adoptive tEansfer
[41, 42]. The functional activity contained within Th superna-
tants which contributes to the differentiation of these effector
cells is attributable to an antigen-specific "helper factor"
(ThF). Unlike cytokines which mediate "help" in an antigen
nonspecific manner, helper factor is antigen-specific: ThF from
3M-i reactive Th cells only contributes to the differentiation of
3M-i reactive CD8 cells, and not the development of CD8
cells of irrelevant antigenic specificity. The ThF must interact
with splenocytes of the same class II haplotype in order to
function. ThF protein is synthesized and secreted by Th cells
and bears epitopes recognized by aIAs antibodies, as well as an
antibody, KJ23, to a TcR beta chain variable domain, V/Mi
[42]. These two epitopes are contained either on two disulfide-
linked polypeptide chains of very similar Mr and isoelectric
point, or on a single polypeptide chain with internal disulfide
bonds [42]. Current studies are focused on determining the
relationship between ThF and the conventional I-A and TcR
polypeptides. Intriguing preliminary data suggests that the ThF
is encoded by a novel rearranging gene, distinct from known
TcR or class II MHC genes [46].
In some circumstances 3M-i specific CD4 T cells can also
effect inflammatory interstitial nephritis. These CD4 effector T
cells are distinct from the CD4 Th. The CD4 Te transfer
DTH responses to 3M-l [39]. They only, however, cause
inflammatory interstitial nephritis following adoptive transfer if
class II MHC expression is first heightened with y-IFN [29].
Studies in murine aTBM disease have shown that strains of
mice nonsusceptible to this disease preferentially differentiate
CD41 3M-I effectot cells [39, 43, 44], The nonsusceptible
phenotype, therefore, does not reflect the absence of sensitized
cells, but rather the absence of 3M-l specific effector cells
which can, under basal conditions, recognize their target anti-
gen in association with class I MHC antigens. The regulatory
phenomena underlying preferential differentiation of CD8 or
CD4 effector T cells in murine aTBM disease is discussed in
the final section.
Autoimmune CD8 effector T cells mediate the spontaneous
nephritis of kdkd mice
One of the implications of low basal levels of class II MHC
antigen expression in native renal cells is that the effector limb
of most forms of T cell-mediated autoimmunity in the kidney
will be mediated by class I-restricted, CD8 T cells. There is
another murine model of interstitial nephritis in which this is
also the case, the spontaneous interstitial nephritis of kdkd
mice. This inbred strain, a mutant of CBAICa mice, inherits, as
an autosomal recessive trait with 100% penetrance, susceptibil-
ity to spontaneous interstitial nephritis [47, 481. This inflamma-
tory lesion is first detectable at 8 to 10 weeks of age and
progresses to widespread cortical involvement. Eventually the
interstitium becomes fibrotic, entrapped glomeruli sclerose, and
the mice become uremic. The demonstration that this disease
could be transferred through radiation bone marrow chimeras
and that thymectomy [48] or protein-calorie restriction [49]
protected young kdkd mice from developing disease, suggested
that cell-mediated immunity was important in disease pathogen-
esis. Further studies have supported this hypothesis. Although
humoral immunity does not contribute significantly to the
immunopathogenesis of interstitial nephritis in kdkd mice [48],
tubular antigen-reactive T cells are present in the peripheral
lymphoid organs and kidneys of diseased kdkd mice [50]. The
predominant effector T cell population in these isolates capable
of mediating interstitial nephritis following adoptive transfer is
CD8, CD4 and class I restricted [50]. As in aTBM disease,
these tubular antigen-reactive CD8 T cells also mediate DTH
to collagenase-solubilized TBM antigens. The target moiety
within the TBM preparation, however, is different from the
3M-i antigen. CD8 effector T cells from kdkd mice recognize
a 56 kDa protein in collagenase-solubilized TBM (C. Kelly,
unpublished data). These studies suggest that interstitial im-
mune injury may be typically initiated by class I-restricted T
cells. Once mononuclear cells have infiltrated the kidney,
released y-IFN, and augmented class II expression, class II
restricted T cells may function to augment and sustain renal
injury.
Mechanisms of interstitial injury by CD8 T cells
The mechanisms underlying CD8 T cell-mediated injury are
active areas of investigation. The 3M-i reactive CD8 T cell
clones characterized in aTBM disease display at least two
distinct functional activities. They mediate delayed-type hyper-
sensitivity responses and they are cytotoxic to tubular epithelial
cells which express 3M-l [39, 40, 45]. Studies in vivo support
the notion that both of these activities may be relevant to how
the kidney is injured. The histology of aTBM associated
interstitial nephritis, whether induced by immunization or
transfer of sensitized T cells, displays focal aggregates of
mononuclear cells which include T cells, B cells, natural killer
cells, and macrophages. These lesions are histologically analo-
gous to a cutaneous delayed-type hypersensitivity reaction. At
times there is granuloma formation as well. Perhaps the most
striking example of granuloma formation in the interstitium is
seen when Lewis rats are immunized with BN renal antigens in
the presence of both PPD and pertussis [51]. This immunization
regimen results in a lesion comprised of macroscopic nodular
lesions, which contain giant cells, epithelioid cells and mono-
nuclear cells. The majority of the T cells in this infiltrate are not
CD8, but rather CD4 T cells [51]. This lesion can also be
transferred by cells.
What are the mechanisms underlying interstitial injury by
these infiltrating immune cells? The aggregate list of cytokines
and enzymes elaborated by such cells continues to grow, but
even the present incomplete list includes a number of proteins
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which have potent effects on the integrity of the interstitial
compartment. Macrophages, for example, secrete a number of
enzymes, such as collagenases, elastases, and lysozymes,
which are capable of tissue damage and may contribute to
progressive interstitial injury [521. A number of cytokines
released by macrophages or T cells (transforming growth factor
f3, tumor necrosis factor a, and interleukin 1) may also elicit
qualitative or quantitative changes in extracellular matrix, and
thereby contribute to interstitial fibrosis [53—561.
The cytotoxic activity of 3M-i reactive T cell clones may well
account for the tubular cell destruction and resultant tubular
atrophy seen in this disease. Cultured cytotoxic T cells synthe-
size proteins with serine esterase activity [57, 58] as well as
pore-forming proteins, which can effect membrane damage
much like the activated membrane attack complex of the
complement cascade [59—61]. Such enzymatic activity provides
a cogent structural explanation for target cell lysis. Recent
evidence suggests these cytolytic proteins are also expressed at
sites of autoimmune inflammation in vivo [62]. Cytotoxicity
provides a direct explanation for tubular cell drop-out, but there
may also be more subtle mechanisms by which cytotoxic cells
injure tubular epithelium. Within the kidney, abnormally-thick-
ened tubular basement membrane, tubular atrophy, and inter-
stitial fibrosis are typically seen in chronic immune-mediated
interstitial nephritis and are the histologic counterpart of irre-
versible loss in renal function [63]. Cytotoxic CD8 T cells may
also display nonlytic effects at low effector:target ratios. They
may alter the physiologic function of the target cell through
cytokine release, in a manner similar to the TDTH described
above. For example, these cells may release cytokines which
affect basement membrane synthesis, alter tubular cell func-
tion, or stimulate the proliferation of interstitial fibroblasts.
Interstitial inflammation in the setting of primary glomerular
disease
Interstitial inflammation is commonly seen in most forms of
progressive glomerular and vascular diseases, and, in many
cases, correlates better with the degree of renal insufficiency
that does the severity of the glomerular lesion [64—66]. Intersti-
tial inflammation is also seen in many experimental models of
glomerular disease, but has not been studied in the same detail
as have the mechanisms of glomerular injury. Recent studies
have linked the mononuclear interstitial infiltrates in proteinuric
lesions to the albuminuria itself [67, 68]. In the nephrotic
syndrome induced by the aminonucleoside of puromycin, mac-
rophages and T cells, predominantly CD8, appear in the
interstitium following the onset of proteinuria. The severity of
this lesion correlates with the degree of proteinuria and cellular
infiltrates subside with resolution of the proteinuria [67]. Ma-
neuvers which decrease the proteinuria, such as administration
of enalapril or low protein diets, also decrease the interstitial
inflammation [69]. Proteinuria induced by other means also has
been associated with interstitial nephritis. In a model of protein-
overload proteinuria, interstitial inflammation develops in the
absence of antibody deposition [68]. The initial infiltrate is
predominantly macrophages, although later CD8 T cells are
also present. T cell depletion did not block the macrophage
component of the infiltrate. The mechanism underlying this
association is not yet clear although it has been postulated to be
a response to tubular epithelial cell injury [68].
Human interstitial nephritis
Interstitial nephritis occurs clinically as either a primary
process or secondary to underlying glomerular disease. Primary
interstitial nephritis is subclassified as either acute or chronic
depending on clinical presentation and whether the interstitial
injury pattern is predominantly inflammatory or fibrotic [70,
71]. In some instances the inflammation characteristic of acute
interstitial nephritis resolves without sequelae, whereas in other
situations it may instead progress to chronic interstitial nephri-
tis.
Most forms of clinically recognized acute interstitial nephritis
occur in association with drug hypersensitivity reactions [72],
infection [731, or systemic autoimmune diseases [74]. The
predominant effector mechanisms in acute interstitial nephritis
is cell-mediated immunity [70, 71], although aTBM antibodies
[75] and immune complexes [76] are occasionally seen as well.
Cell-mediated immunity has been implicated by the findings of
both in vivo (DTH) and in vitro (lymphoblast transformation)
evidence of hypersensitivity to specific inciting antigens [72,
77]. Several series have been published examining the pheno-
type of infiltrating mononuclear cells in interstitial nephritis of
different etiologies [78—83]. Several generalizations can be
drawn from these studies. In most examined cases of interstitial
nephritis in humans, the majority (> 50%) of the infiltrating
mononuclear cells are T lymphocytes. The remaining cells are
predominantly monocytes, with significant numbers of B cells,
plasma cells, or natural killer cells seen only occasionally. In
most cases the CD4ICD8 ratio of the interstitial infiltrate is at
least one, and usually greater than one. Several studies have
observed lower CD4/CD8 ratios in NSAID-associated intersti-
tial nephritis, than interstitial nephritis related to metabolic
derangements, granulomatous, or autoimmune diseases [78,
81]. Since there is no known functional correlate for the
CD4/CD8 ratio, it is unknown what the implications of this
measurement are, especially since experimental work has
clearly shown that T cell phenotype correlates poorly with
classically assigned functions in interstitial disease [39, 50]. The
predominant T cell population may also be affected by immu-
nosuppressive therapy prior to biopsy, or the stage of disease at
the time of biopsy. Steroids in particular can markedly deplete
the number of lymphocytes seen in interstitial nephritis. Both
infiltrating T cells and tubular epithelium express class II MHC
antigens in interstitial nephritis [78, 83]. Expression of class II
MHC is seen in under 5% of tubular cells from normal kidneys.
As discussed earlier, such expression may allow tubular epithe-
hal cells to act as antigen-presenting cells under some condi-
tions and thereby perpetuate autoimmune injury.
The major impediment to a comprehensive understanding of
the role of cell-mediated immunity in human interstitial disease
is the difficulty in defining the antigenic specificity of T cells.
Measuring proliferation responses of peripheral blood mononu-
clear cells to various antigens is a notoriously insensitive way of
assessing the reactivities of T cells present at an inflammatory
site, and it is technically difficult to generate enough T cells
from renal tissue to perform all necessary experiments. Our
knowledge, therefore, of the human antigens which elicit or are
the target of interstitial T cells is quite incomplete. Based on
current theories of how autoimmune reactions are initiated, one
can hypothesize that certain drugs or infectious agents elicit
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inflammatory interstitial injury in a small percentage of the
population because those individuals can mount cell-mediated
immune responses to those exogenous antigens which cross
react with native renal antigens. Alternatively, drugs or infec-
tious agents may alter host antigens or, through nonspecific
tubular cell damage, expose host antigens to which the host is
not tolerant. It has been suggested, for example, that Tamm-
Horsfall protein may represent a target antigen for infiltrating T
cells, since it is found in an abnormal location (within interstitial
infiltrates) in several tubulointerstitial diseases, including med-
ullary cystic disease, chronic obstructive pyelonephritis, hydro-
nephrosis, and chronic "idiopathic" tubulointerstitial nephritis
[84].
B cell response to interstitial antigens
Initial studies of immune mediated interstitial disease focused
on characterizing antibodies reactive with tubular and intersti-
tial determinants [85—89]. In addition to providing important
correlative data about specific antibody responses and expres-
sion of disease, these studies in aggregate generated a bank of
reagents which allowed for purification of target antigens (re-
viewed by C Wilson, this issue). Unlike the case with glomer-
ular disease, antibodies to interstitial determinants are rarely
present without an accompanying mononuclear cell infiltrate.
Their role as an independent effector mechanism of disease,
therefore, has been assessed largely by adoptive transfer of
polyclonal immune serum. This section will summarize the
characteristics and nephritogenicity of various antibody speci-
ficities relevant to interstitial disease.
Antibodies recognizing tubular basement membrane antigens
Several aspects of the humoral response in aTBM disease
have undergone experimental scrutiny. These may be arbitrar-
ily grouped into three categories. The first is those events
required for induction of the antibody response and the defini-
tion of target antigen recognition. The second category includes
studies on antibodies as effector mechanisms of autoimmunity.
The final category includes work characterizing second order
antibody responses directed to aTBM antibodies (or anti-
idiotypic responses) which typically downregulate first order
antibody responses and may modulate the expression of disease
[90—92]. In aggregate, this work has been performed in guinea
pig, rat, and murine models of aTBM disease. Such studies
have demonstrated some aspects of the aTBM antibody re-
sponse relevant only to certain rodent species, and other
findings which are broadly shared between species. Since all
findings are of equal potential relevance to human disease, the
work will be summarized here as a composite sketch of aTBM
antibody responses.
aTBM antibody responses are typically induced by immuni-
zation with cortical tubular basement membranes in adjuvant.
Multiple sources of TBM have been used, including rabbit [93],
bovine [86], and rat [10]. Tolerance mechanisms prevent TBM
from the species and strain being immunized from being highly
immunogenic, so animals are typically immunized with heter-
ologous antigen. All species studied develop an aTBM antibody
response following immunization with an immunogenic form of
TBM. This response is measured both by examination of
circulating Ab titers and demonstration, by direct immunofluo-
rescence, of linear staining of the TBM with IgG Ab. In most
cases, renal deposition of aTBM antibodies occurs whenever
circulating Ab is detectable. This implies that the target antigen
in vivo is typically visible to circulating antibody. An interesting
exception to this statement exists in inbred strains of rats, and
probably in some humans as well. Lewis rats do not express the
target antigen recognized by aTBM antibodies in their kidneys
[10, 11], at least not in a form accessible or recognizable by
polyclonal or monoclonal aTBM Ab. When Lewis rats are
immunized with TBM in adjuvant, they mount detectable
circulating aTBM-Ab responses, but the renal immunofluores-
cence is negative. This polymorphism in TBM Ag expression
has been exploited in studies analyzing mechanisms of toler-
ance to organ-specific antigens [94]. When TBM Ag kidneys
[from (Lew x BN) F1 animals] are transplanted into Lewis rats,
the recipients mount an aTBM antibody response, since they
are not tolerant to this polymorphic antigen [95]. A similar
phenomenon has been described in patients (TBM Ag) who
are transplanted with TBM Ag kidneys [12]. Genetic studies in
inbred rats demonstrated that this alloantigen is linked to the
genes for albinism and pinkeye, on the first linkage group [96,
97] and not to the rat MHC [98, 99]. It is inherited in a dominant
manner.
The biochemical and molecular nature of the antigen recog-
nized by aTBM antibodies is an area of continued investigative
interest. The target antigen is preserved following collagenase
digestion of partially-purified TBM preparations. Using immu-
noaffinity chromatography with a monoclonal aTBM Ab, and
the property of differential recognition of BN and LEW kid-
neys, a 48 kDa Ag, called 3M-l, was isolated from collagenase
solubilized rabbit TBM preparations [100]. This antigen local-
izes, by immunoelectronmicroscopy, to the most lateral aspects
of the TBM bordering the interstitium, and does not appear to
be an integral part of the TBM proper [100]. A glycoprotein of
the same molecular weight has been isolated from human TBM,
and shown to be reactive with two human cTBM antisera, but
not antisera with cGBM reactivity [101, 102]. Although a given
antisera will recognize this antigen in TBM from multiple
species, there is some heterogeneity in antigenic size between
species. As described above, TBM Ag from rabbit and human
kidneys is about 48 kD. The rat antigen is about 42 to 45 kD
[89], and the mouse antigen approximately 30 kD [25, 103].
Antibody screening of an expression cDNA library made from
murine tubular epithelial cells has isolated a group of cDNA
which define the TBM antigen as a complex, novel structure
containing five distinct amino acid termini, all sharing a com-
mon framework domain. In situ hybridization studies demon-
strate that this gene is transcribed in tubular epithelium. The
framework domain of this eDNA encodes a protein which
shares a 37% non-repetitive structural similarity with some
intermediate filament-associated proteins [104]. Peptides syn-
thesized from open reading frames in this eDNA are recognized
by both aTBM antibodies as well as murine T cell clones with
specificity for 3M-I [45, 104]. This molecular information
should now facilitate an analysis of factors controlling expres-
sion of the TBM target antigen.
aTBM antibodies will transfer aTBM disease with interstitial
nephritis in guinea pigs [85, 87], and to a lesser degree in rats.
Studies in guinea pigs demonstrated that either IgG1 or IgG2
antibodies were effective in adoptive transfer of disease [88] and
that depletion of C3 with cobra venom factor inhibits disease
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expression [105]. Adoptive transfer of disease into BN rats with
Lewis aTBM antisera has been examined from the standpoint
of quantitation of antibody deposited [106]. cTBM antibodies
are detectable in the kidney by 24 hours following transfer with
the quantity of IgG deposited increasing over the following six
days. The fully developed cellular lesion included PMN's,
mononuclear cells, and giant cells, as well as C3 deposition.
Complement depletion of the aTBM antisera recipients with
cobra venom factor had no effect on aTBM antibody deposi-
tion, but markedly attenuated the cellular infiltration [106]. This
work points to a major effector mechanism whereby aTBM
antibodies elicit interstitial inflammation and tissue damage:
activation of complement with the resultant attraction of
PMN's and mononuclear cells into the interstitium. aTBM
antibodies can also act as a bridge between the humoral and
cellular immune response via antibody-dependent cell-mediated
cytotoxicity reactions [107]. In this regard, it is interesting that
the complement cascade may be activated by ammonia, levels
of which may be elevated in the interstitium in chronic renal
failure [108]. This may be a partial explanation for the cellular
infiltrate often seen in the interstitium in a variety of chronic
renal diseases.
The TBM-reactive B cell repertoire has been quantitatively
assessed in BN rats through the analysis of a library of rat
aTBM antibodies, all of which are specific for the 3M-l TBM
antigen [92]. These studies indicated the presence of approxi-
mately 58 distinct clones involved in the B cell ctTBM response
and also demonstrated biased VH gene usage among these
autoantibodies. Epitopic recognition of 3M-i by these mono-
clonals, however, was strikingly similar, in that almost all the
monoclonal aTBM-Ab competitively inhibited 3M-i recogni-
tion by a reference monoclonal. A cross reactive idiotype is
present on these monoclonals, a finding exploited for its thera-
peutic potential [92].
The aTBM antibody response has also been evaluated in
various strains of immunized mice [371. Unlike the situation
described above for guinea pigs and rats, aTBM antisera does
not transfer disease in mice. A comparative analysis of the
aTBM antibody response in strains of mice susceptible and
non-susceptible to aTBM disease revealed no significant differ-
ences in tTBM antibody titer, epitopic specificity of the aTBM
Ab, or expression of the cross reactive idiotype [371. As
described above, aTBM antibodies may even subserve a pro-
tective function in immunized mice, since they decrease class II
MHC expression by tubular epithelium [29]. In nonsusceptible
mice, aTBM deposits are present in the kidney, but there is no
accompanying cellular infiltration [40].
It is unclear whether aTBM antibodies seen clinically in
various types of renal disease are themselves of pathogenic
significance. Typically such deposition is seen in four different
settings. Linear deposition of sTBM antibodies is seen in 70%
of patients with cGBM disease, and probably include several
specificities [109, 1101. Several cases of drug-associated inter-
stitial nephritis have been reported to show linear aTBM
antibody staining [75, 111, 112], but the majority of drug-
associated interstitial nephritis does not show these deposits.
aTBM deposits without aGBM deposits occur rarely as a
primary disease, and in this case the antigen recognized appears
to be 3M-i [101, 1021. Most commonly, however, cTBM
deposits occur in the setting of renal transplantation. Some-
times this antibody response defines antigenic differences be-
tween the native and engrafted kidneys [12] whereas in other
cases such polymorphisms are not detectable. aTBM antibod-
ies do not appear to cause predictable changes in length of
successful engraftment.
aTBM antibodies can also be seen as neoantigens which
themselves can induce an antibody response. If such a response
is directed to the hypervariable, antigen-binding region of the
antibody (or idiotype) it is termed an anti-idiotypic response.
Anti-idiotypic responses typically downregulate the production
of the primary antibody (that which expresses the idiotype).
Anti-TBM antibody titers and disease expression can be down-
modulated by heterologous anti-idiotypic antisera in both
guinea pig and rat models [91, 92]. Induction of an autologous
anti-idiotypic response in susceptible mice by injection of
idiotype-bearing lymphoblasts has the same effect [113]. Inter-
estingly, BN rats immunized to produce disease do not typically
generate an autologous anti-idiotypic antibody response [114].
The lack of such a response is attributable to the action of
cyclophospharnide sensitive, 0X8 suppressor T cells, which
appear to leave the nephritogenic immune response in an active
mode. As described above, the majority of the aTBM antibod-
ies generated following immunization of BN rats share a cross
reactive idiotype (a structure also expressed on 3M-i reactive T
cells). A rabbit anti-idiotypic antisera directed toward this set of
variable region determinants was effective both as a prophylac-
tic regimen to abrogate disease and as a therapeutic modality to
arrest the progression of disease [92].
Other B cell responses implicated in immune-mediated
interstitial disease
Immune complex and complement deposition in the TBM
and interstitial vessels is seen in patients with SLE [76, 110], as
well as in the various murine models of lupus [1151. Typically
these deposits have a granular and discontinuous appearance by
immunofluorescence and electron microscopy, although rarely
linear deposition of TBM antibodies has been described in
SLE [116]. These complexes are variably accompanied by
cellular infiltrates within the interstitium, and are almost always
seen in the presence of glomerular immune complex deposits
and glomerular damage. Occasionally the interstitial involve-
ment in SLE may predominate over glomerular pathology [1171.
Two other renal tubular cell antigens have been implicated in
local immune complex formation in the interstitial compart-
ment, the Heymann antigen of the brush border [118] and
Tamm-Horsfall protein in the thick ascending limb and distal
convoluted tubule [1191. Animals immunized to produce Hey-
mann's nephritis have IgG and C3 deposits along the tubules
[120] and often have a striking mononuclear cell infiltrate in the
interstitium as well [1211. Antibody deposition in this disease is
likely dependent on glomerular proteinuria, allowing antibody
access to the tubular lumen. Indeed, if animals proteinuric from
serum sickness are administered sFxla antibodies, these anti-
bodies gain access to the tubular lumen and mediate comple-
ment independent lysis of tubular cells [122, 123]. Similar
findings have been made with antibodies to Tamm-Horsfall
proteins in proteinuric rats [124]. Rats or mice immunized with
Tamrn-Horsfall protein develop immune deposits at the bases of
ascending limb cells [125, 126]. Rabbits develop an interstitial
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nephritis following such immunization, although they do not
develop immune deposits [127]. The finding of abnormal local-
ization of Tamm-Horsfall protein in the interstitium in the
setting of urinary tract obstruction or reflux nephropathy sug-
gests that it may be an important target antigen in previously
damaged kidneys [841.
Regulation of immune responses targeted to the interstitium
Regulation of autoimmune B or T cell responses may occur
either during the maturational phase of the response or on fully
differentiated effector mechanisms. The term regulation is a
broad one and encompasses both mechanisms endogenous to
the host immune response, as well as external manipulations
which bidirectionally modify the immune response in an antigen-
specific or nonspecific manner [7]. Endogenous host immunoreg-
ulation plays a critical role in determining host susceptibility to
autoimmune interstitial nephritis [8]. External manipulations
which alter immune responses targeted to interstitial antigens have
been studied largely as therapeutic modalities and therefore tend
to be inhibitory modalities. The following section is divided into
two parts. The first will detail our current understanding of
endogenous host mechanisms which regulate immune responses
targeted to the interstitium and therefore affect the balance be-
tween tolerance and autoimmunity. The second section will dis-
cuss therapeutic modalities which regulate the immune response
to interstitial antigens.
Immune regulation and tolerance to interstitial glycoprotein
antigens
A host does not typically mount sustained immune responses
to its own self antigens. This phenomenon is called immune
tolerance and it remains one of the central unresolved questions
in immunology [128]. There are several theories proposed to
account for the phenomenon of tolerance including thymic
deletion, clonal anergy, and active suppression by regulatory T
cells. These theories are not mutually exclusive and, in fact, it
would be advantageous for a host to have multiple mechanisms
for preventing autoimmune injury. The importance of each
mechanism may vary for a given antigen. T cells bearing antigen
receptors which have high affinity recognition for thymic epi-
thelial antigens, for example, appear to be deleted during
thymic ontogeny [129]. However in transgenic mouse models in
which tolerance to non-thymic antigens has been evaluated,
thymic deletion does not appear to be the underlying mecha-
nism [130, 131]. In such cases, peripheral inactivation of T or B
cells accounts for clonal silencing. This observation simply
redefines the problem of tolerance into one of understanding
mechanisms of clonal anergy. Alternative signalling pathways
may result in an anergic, rather than proliferative state [132].
Anergy may also be the end result of specific suppressor T cell
effects [94, 133]. In several models of autoimmune interstitial
nephritis, there is abundant evidence that peripheral inactiva-
tion of autoreactive clones is tightly linked to the action of
suppressor T cells.
aTBM disease in rats provides an intriguing model in which
to study the mechanisms underlying tolerance to parenchymal
self antigens. As mentioned previously, the target TBM antigen
of this disease is not expressed in all inbred rat strains [10, 11].
The immune response to rat 3M-i can be compared in rats
expressing and not expressing the 3M-i antigen. Brown Nor-
way rats express the TBM antigen (TBM) and do not mount an
immune response when immunized with self antigen (BN-TBM)
emulsified in complete Freund's adjuvant [94]. This unrespon-
siveness extends to both the B and T cell compartments.
LEW.IN(T) rats (MHC identical to BN and neonatally toler-
ized to BN alloantigens), which do not express the TBM
antigen, generate both a T and B cell response following
immunization with BN-TBM. LEW. 1N(T) animals immunized
with BN-TBM do not develop interstitial nephritis, since there
is no expressed target antigen in the interstitium for these
immune cells and antibodies to recognize. These BN-TBM
reactive T cells, however, were a reagent by which to assess the
absence of T cell reactivity in BN rats immunized with self
antigen. Admixture experiments demonstrated that this ab-
sence of reactivity in the BN rat was attributable to a BN
suppressor T cell, and not to clonal deletion [94]. The BN Ts
cell is CD8 and MHC restricted in its function. Its physiologic
importance in maintaining tolerance to the 3M-i glycoprotein is
supported by two pieces of evidence. First, TBM animals do
not have 3M-I reactive Ts cells. From a teleologic standpoint,
they would serve no function. Secondly, if the function of this
BN Ts cell is abrogated with cyclophosphamide, BN rats
develop severe interstitial nephritis following immunization
with self antigen [94]. While these studies do not eliminate a
role for clonal deletion in tolerance to nonthymic antigens, they
clearly demonstrate that clonal deletion alone cannot explain
this state of unresponsiveness.
This observation is not unique to aTBM disease. A similar
situation exists in the spontaneous interstitial nephritis of kdkd
mice [30, 31]. As described above these animals mutated from
CBA/Ca mice and inherit, as an autosomal recessive trait, the
susceptibility to spontaneous interstitial nephritis. CD8
splenic T cells from non-disease prone C BA/Ca mice inhibit the
expression of interstitial nephritis in kdkd mice [133]. If the
CBA/Ca suppressor cells are eliminated from the CBA/Ca
splenic CD8 population, the remaining cells mediate severe
interstitial nephritis. Therefore, CBA/Ca mice harbor in their
peripheral lymphoid organs CD8 T cells fully capable of
causing interstitial injury. The fact that they do not typically
develop disease relates, at least in part, to the actions of specific
suppressor T cells.
Interestingly, however, T cells with identical suppressor
function are also demonstrable in kdkd mice prior to disease
onset. Disease susceptibility, therefore, could not be simply
attributed to an absence of Ts cells in kdkd mice, but rather to
loss of their function. Such a loss could, in theory, occur
because of failure of Ts cells to respond to signals, Ts depletion
by autoantibodies, or through the action of opposing regulatory
T cells [134, 135]. Although there was not evidence of anti-Ts
antibodies in kdkd sera, there was strong evidence for counter-
regulatory T cells. T cells which negate the effects of suppressor
cells have been functionally characterized in many antigenic
systems [136—1403. They have been variably christened "con-
trasuppressor" (Tcs) or "anti-suppressor" T cells [1411. This
regulatory subset is distinct from helper T cells in that Tcs have
no discernible function in the absence of Ts cells. Their
mechanism of action is unclear but appears to be mediated
through a secreted protein which has antigen binding capabili-
ties but is distinct from either chain of the TcR. This factor may
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competitively inhibit a suppressor protein of similar structure
[142]. Tcs cells in all systems studied bear a common pheno-
typic characteristic, the ability to adhere to the Vicia Villosa
lectin. Such adherence is dependent on the expression of
N-acetyl-d-galactosamine at termini of either N- or 0-linked
oligosaccharides [1431. When kdkd splenocytes are fractionated
using the VV lectin, one can demonstrate the presence of
antigen-specific, functional contrasuppressor T cells in kdkd
mice. The appearance of this subset closely correlates with the
onset of disease activity. In the presence of VV lectin binding
cells from kdkd mice, bulk populations of CBA/Ca splenocytes
become nephritogenic, that is, kdkd Tcs cells abrogate the Ts
cells in the nonsusceptible host. Conversely, if VV lectin
binding cells are removed from kdkd splenocytes, the remaining
population contains both Ts and effector CD8 clones and the
net effect is a suppressed nephritogenic immune response [133].
Presence of absence of this disease, therefore, is tightly linked
to the relative expression of regulatory T cell subsets, and not
to the presence or absence of effector T cells. These findings
again argue strongly against a thymic deletion model as the sole
means for maintaining tolerance to parenchymal self antigens.
Histologic and genetic similarities between the animal model of
kdkd nephritis and human medullary cystic disease suggest that
similar regulatory abnormalities may underlie the human dis-
ease [144].
Immune regulation and the differentiation of effector T cells
T cells also play an important regulatory role in the differen-
tiation of 3M-i specific T cells in strains of mice susceptible and
nonsusceptible to crTBM disease. As described above, the
humoral responses in these strains are indistinguishable so that
a difference in antibody titer or ligand affinity cannot explain
susceptibility differences [37]. The T cell responses of suscep-
tible (SJL) and nonsusceptible {Bl0.S(8R)] are very different.
B1O.S(8R) mice preferentially expand CD4 3M-l reactive
effector cells whereas SJL mice preferentially expand CD8
effector cells. This phenotypic difference is important since
class II restricted T cells typically do not injure the kidney,
given the low basal levels of tubular cell class II MHC antigen
expression [29, 39]. Both CD8 and CD4 effector T cells are
initially demonstrable in peripheral lymph nodes following
immunization of either SJL or B10.S(8R) mice [39]. The further
differentiation and expansion of these subsets is differentially
regulated in SJL and BlO.S(8R) mice such that one subset then
preferentially expands. This process is termed "phenotype
selection" and it is also mediated by 3M-i specific T cells [43,
44]. The expression of these regulatory T cells is markedly
different in SJL and B10.S(8R) mice. Both SJL and BiO.S(8R)
mice express a 3M-i specific, CD8 suppressor T cell which
functions to suppress potentially self-injurious CD8 effector
cells [43, 44]. This suppression allows, in non-susceptible mice,
for the preferential expansion of CD4 effector cells. In sus-
ceptible mice, these suppressor cells are counteracted by Vicia
Villosa lectin adherent contrasuppressor cells, which negate
suppressor cell function and allow for preferential maturation of
CD8 T cells [44]. Contrasuppressor activity maps to H2Ks,
the same class I MHC locus to which susceptibility maps,
raising the intriguing possibility that, in some cases, the func-
tional correlate of MHC-linked susceptibility to autoimmune
diseases may be T cell regulation.
Regulation of the immune response by exogenous factors
Immune responses targeted to the interstitium can be down-
regulated by many of the common immunosuppressive modal-
ities used clinically. In addition to such pharmacologic immu-
nosuppression, there are also experimental manipulations
which result in potent immunosuppression. These latter modal-
ities include both antigen-specific and antigen-nonspecific mo-
dalities. This section will discuss the efficacy of these various
immunosuppressive regimens and what is known about their
mechanism of action.
Antigen-nonspecific immunosuppression
Antigen nonspecific modalities which are effective in exper-
imental aTBM disease include cyclophosphamide [145], cyclo-
sporine [146—148], prostaglandin E1 [149, 150], and protein-
calorie restriction [151]. Cyclophosphamide completely blocks
the development of interstitial nephritis when administered to
BN rats immunized to produce disease. The drug also inhibits
disease progression if treatment is initiated following disease
onset [1451. Cyclophosphamide predominantly inhibits cell-
mediated immunity in this model, and since the B cell response
is T cell dependent, if drug is administered from the time of
immunization, the aTBM antibody response is also inhibited.
An intriguing observation from the cyclophosphamide experi-
ments was that a low dose of cyclophosphamide actually
enhanced the degree of interstitial injury [145]. The mechanism
underlying such enhancement may be the well known sensitiv-
ity of some Ts cells to cyclophosphamide [151].
POE1 also preferentially inhibits cell-mediated immunity in
mice immunized to produce aTBM disease. Even when this
agent is administered form the time of immunization, no detect-
able difference in aTBM antibody titers or amount of aTBM
deposits exist between PGE1-treated and control animals [149].
The inhibitory effect of POE1 on cell-mediated immunity occurs
in a discrete time period, the first week following immunization.
The agent need only be administered during this week to inhibit
disease expression 12 weeks later. In vitro studies demon-
strated that PGE1 inhibits CD8 effector cell differentiation in a
dose-dependent, reversible manner. PGE1 does not induce
suppressor T cells in this system but rather stimulates T cells to
release cytokines with inhibitory activity. This inhibition can be
overcome by recombinant IL-l [149]. PGE1 also has beneficial
immunosuppressive effects in some models of murine lupus
nephritis [152, 153]. The observation that a diet rich in omega-3
fatty acids reduces the severity of murine lupus may also
related to changes in certain prostaglandin species [154].
Other nonspecific immunosuppressive modalities consist of
antibodies which target certain subsets of T cells and/or inter-
fere with T cell activation. Antibodies to CD4, a cell-surface
glycoprotein found on most helper T cells ( of total T cells)
can either prevent or ameliorate (depending administration
protocol) the lupus syndrome of NZBINZW F1 mice [155, 1561.
Anti-Ia (class II MHC antigens) antibodies have also proved to
be effective therapies in several autoimmune disease models,
including NZB/NZW Fl mice and mice immunized to produce
allergic encephalomyelitis [157, 158]. The anti-Ia antibodies
presumably interfere with antigen recognition by class II-
restricted T cells, and not directly with the T cell surface, since
murine T cells do not express class II on their surface. Such
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interference by anti-class II antibodies with T cell antigen
recognition may well occur at the level of the target organ, given
the common finding of increased class II expression on parenchy-
mal cells involved in inflammatory responses [159—161].
Another antigen-nonspecific, but more highly targeted, mo-
dality concerns the use of antibodies to the IL-2 receptor and
IL-2 chimeric toxins [162]. IL-2 is a key cytokine for T cell
activation in that it stimulates antigen-activated T cells to
proliferate. High affinity receptors for IL-2 are only expressed
on activated T cells. Antibodies to a subunit of this high affinity
IL-2 receptor protect NZB/NZW F1 mice from developing renal
injury [1631. These antibodies also display beneficial immuno-
suppressive effects in the NOD model of insulin dependent
diabetes mellitus [163], and in cardiac transplants engrafted across
MHC barriers [164]. A related and potentially more efficacious
targeted therapy is the IL-2 chimeric toxin. This protein is the
result of a gene fusion between the IL-2 cDNA and part of the
diphtheria toxin structural gene [165]. This toxin inhibits protein
synthesis (by the same mechanism as does intact diphtheria
toxin), but only affects cells bearing the IL-2R [166]. This toxin
appears to be an even more potent immunosuppressive agent for
IL-2R cells than the anti-IL-2R antibodies [162].
Antigen-specific immunosuppression
Antigen-specific immunosuppression has been achieved ex-
perimentally by a variety of methods, including immunization
with large amounts of tubular antigen in incomplete Freund's
adjuvant [167], by injection of tubular antigen-reactive T lym-
phoblasts which bear a cross reactive idiotype [113], with
anti-idiotypic antisera [92], and with induced suppressor T cell
networks [168—172]. The structure of these Ts networks in the
murine aTBM disease model has been delineated in some
detail. Suppressor T cells are induced in susceptible mice
following intravenous injection of splenocytes to which tubular
antigens have been chemically coupled with l-ethyl-3-(3-dimeth-
ylaminopropyl) carbodiimide [168]. Such antigen presentation
induces two types of suppressor T cells which are phenotypi-
cally and functionally distinct. Suppressor inducer cells (Tsl)
bear the CD4 phenotype and express an idiotype cross reac.
tive with that found on Ig eluted from nephritic kidneys. The
Ts 1 cells inhibit an early stage in the differentiation of the CD8
nephritogenic effector cells and also function to induce a
population of CD8 suppressor effector lymphocytes (Ts2)
[168, 171]. Suppression by the CD4 suppressor cells is medi-
ated by an antigen-binding soluble protein factor [169]. This Ts
protein bears epitopes recognized by antibodies against TcR
beta chain variable region gene products. Its size, however (60
to 76 kDa depending on state of reduction), is considerably
larger that the TcR beta chain. At a protein and molecular level,
therefore, the relationship of this suppressor protein to the TcR
requires clarification. Suppression by this TsF, as well as the
TsF produced by Ts2 cells, requires new mRNA and protein
synthesis [45, unpublished data]. Suppression can therefore be
seen as an active event, occurring perhaps through the synthe-
sis of proteins involved in regulating T cell activation. This Ts
network is very effective at both preventing [168] and amelio-
rating the expression of murine aTBM disease [170]. Induction
of these Ts networks does not require a highly purified antigen.
This finding, coupled with the demonstrated therapeutic effi-
cacy following disease onset, makes Ts networks a highly
attractive form of antigen-specific immunosuppressive therapy.
Future horizons
Although the past decade has witnessed major advances in
our understanding of immune-mediated interstitial disease,
there are a number of challenges which lie ahead. The close
correlation between interstitial damage and progressive renal
dysfunction provides a compelling mandate for continued in-
tensive investigation in this area. The simplification and demys-
tification of standard immunologic and molecular techniques
should facilitate the definition of target antigens in human
interstitial disease, mechanisms of immune recognition and
effector function, and signals for interstitial fibrosis. Above all
else, new insights into immune mechanisms of interstitial dam-
age must be incorporated into the design of novel therapeutic
modalities which may obviate progressive injury. While model
systems will continue to be the major arena in which investiga-
tions into immune mechanisms are conducted, the value of this
work will be augmented considerably if it has a positive impact
on clinical practice.
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